Expression of miR-143 and miR-145 and their functional study in gastric carcinoma / 中华胃肠外科杂志

<p><b>OBJECTIVE</b>To investigate the expressions of miR-143 and miR-145 in gastric cancer tissues and their biological functions.</p><p><b>METHODS</b>A set of gastric cancer metastasis-related miRNAs was screened by comparing the miRNA profiles between the primary gastric cancer and matched liver metastasis. Among these miRNAs, expressions of miR-143 and miR-145 were further validated. The influence on metastasis was analyzed by transwell assay.</p><p><b>RESULTS</b>Expressions of miR-143 and miR-145 down-regulated significantly in gastric cancer tissues compared to adjacent normal tissues(miR-143, 0.028±0.005 vs. 0.052±0.014, P=0.058; miR-145, 0.922±0.135 vs. 1.722±0.285, P=0.007), and decreased significantly in the metastatic lesion compared with the primary lesion(miR-143, 0.059±0.025 vs. 0.182±0.045, P=0.021; miR-145, 0.164±0.076 vs. 0.594±0.283, P=0.042). Expressions of miR-143 and miR-145 were significantly correlated(r=0.400, P=0.000), and they synergistically inhibited gastric cancer cell migration.</p><p><b>CONCLUSION</b>miR-143 and miR-145 may take part in the progression of gastric cancer metastasis, and they may have synergetic effects.</p>

Detection of serum endothelial cell specific molecule 1 in gastric cancer patients and its clinical significance / 中华胃肠外科杂志

<p><b>OBJECTIVE</b>To investigate the expression of serum endothelial cell specific molecule 1 (ESM-1) in gastric cancer and to evaluate the effect of serum ESM-1 as a potential serum biomarker.</p><p><b>METHODS</b>Serum ESM-1 was detected by enzyme-linked immunosorbent assay (ELISA) and CEA, CA19.9, CA72.4 were detected by electrochemiluminescence immunoassay (ECLIA) in 102 patients with gastric cancer preoperatively. At the same time, serum ESM-1, CEA, CA19-9, CA72-4 in 41 healthy adults volunteers were detected with the same method. In addition, the follow-up data of all the patients were collected.</p><p><b>RESULTS</b>Compared to healthy volunteers, the serum ESM-1 level in gastric cancer patients increased (P<0.01). The sensitivity and specificity of serum ESM-1 were 73.9% and 51.2% respectively. In contrast, the sensitivities of CEA, CA19-9 and CA72-4 were only 16.1%, 18.3% and 23.2% respectively. High level of serum ESM-1 indicated poor outcomes (P<0.05).</p><p><b>CONCLUSIONS</b>Serum ESM-1 increases in the peripheral blood of the gastric cancer patients. It may be a potential serum marker to help diagnosis and prediction of prognosis of gastric cancer patients.</p>